HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Mendoza, Q. P. Articles by Griffin, D. E. Search for Related Content PubMed PubMed Citation Articles by Mendoza, Q. P. Articles by Griffin, D. E. Agricola Articles by Mendoza, Q. P. Articles by Griffin, D. E.

Monoclonal Antibodies to the E1 and E2 Glycoproteins of Sindbis Virus: Definition of Epitopes and Efficiency of Protection from Fatal Encephalitis

Departments of Medicine and Neurology, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, U.S.A.

Protection of mice from fatal neuroadapted Sindbis virus encephalitis can be accomplished by passive transfer of monoclonal antibodies (MAbs) to either the E1 or E2 glycoprotein of Sindbis virus. Both neutralizing and non-neutralizing MAbs can be protective. To define further the characteristics of MAbs that provide protection from fatal disease, antigenic epitopes on the E1 and E2 glycoproteins were identified using a competitive binding enzyme immunoassay. Four distinct epitopes on E1 and three on E2 were defined. MAbs to all E1 epitopes, both neutralizing (three) and non-neutralizing (one) protected mice from fatal encephalitis. MAbs to the E2 neutralizing epitopes (two) protected mice from fatal encephalitis while those to the non-neutralizing epitope did not. The efficiency of protection from fatal Sindbis virus encephalitis of four neutralizing and non-neutralizing protective anti-E1 and anti-E2 MAbs representing different epitopes was compared. The neutralizing MAbs (against epitopes E2-ab, E2-c and E1-c) gave 50% protection at lower doses (2 to 20 µg) than the non-neutralizing MAb representing epitope E1-e (150 µg) when given before virus challenge. When given after virus challenge, MAbs to E2-ab and E2-c protected at lower doses (0.03 to 0.3 µg) than did either MAbs to E1-c (> 100 µg) or E1-e (10 µg). The MAbs to E1-e, E2-ab and E2-c were required in larger amounts to afford protection before than after challenge, while the opposite was true for MAb to E1-c.

Keywords: monoclonal antibodies, Sindbis virus, glycoprotein epitopes

Received 13 June 1988; accepted 26 September 1988.

This article has been cited by other articles:

				D. J. Pierro, E. L. Powers, and K. E. Olson Genetic determinants of Sindbis virus strain TR339 affecting midgut infection in the mosquito Aedes aegypti J. Gen. Virol., May 1, 2007; 88(5): 1545 - 1554. [Abstract] [Full Text] [PDF]

				K. M. Myles, D. J. Pierro, and K. E. Olson Deletions in the Putative Cell Receptor-Binding Domain of Sindbis Virus Strain MRE16 E2 Glycoprotein Reduce Midgut Infectivity in Aedes aegypti J. Virol., August 15, 2003; 77(16): 8872 - 8881. [Abstract] [Full Text] [PDF]

				L. Hammar, S. Markarian, L. Haag, H. Lankinen, A. Salmi, and R. H. Cheng Prefusion Rearrangements Resulting in Fusion Peptide Exposure in Semliki Forest Virus J. Biol. Chem., February 21, 2003; 278(9): 7189 - 7198. [Abstract] [Full Text] [PDF]

				P. Lee, R. Knight, J. M. Smit, J. Wilschut, and D. E. Griffin A Single Mutation in the E2 Glycoprotein Important for Neurovirulence Influences Binding of Sindbis Virus to Neuroblastoma Cells J. Virol., May 13, 2002; 76(12): 6302 - 6310. [Abstract] [Full Text] [PDF]

				F. Verrier, A. Nadas, M. K. Gorny, and S. Zolla-Pazner Additive Effects Characterize the Interaction of Antibodies Involved in Neutralization of the Primary Dualtropic Human Immunodeficiency Virus Type 1 Isolate 89.6 J. Virol., October 1, 2001; 75(19): 9177 - 9186. [Abstract] [Full Text] [PDF]